• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Guardant Health Inc (NQ: GH )

    28.41 -0.46 (-1.59%)
    Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 736,424
    Open 28.82
    Bid (Size) 27.50 (1)
    Ask (Size) 28.78 (5)
    Prev. Close 28.87
    Today's Range 28.09 - 28.83
    52wk Range 15.81 - 41.06
    Shares Outstanding 101,298,669
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Biotech Moonshots With Imminent Catalyst Potential
    Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts. 
    Via InvestorPlace
    The 3 Best Personalized Medicine Stocks to Buy in July 2024
    Explore promising personalized medicine stocks poised for growth as the industry expands, driven by advancements in genomic technologies. 
    Via InvestorPlace

    Performance

    YTD
    +7.17%
    +7.17%
    1 Month
    +3.65%
    +3.65%
    3 Month
    +44.21%
    +44.21%
    6 Month
    +11.94%
    +11.94%
    1 Year
    -21.84%
    -21.84%

    More News

    Read More
    From ‘Sell’ to ‘Strong Buy’: 3 Dramatic Analyst U-Turns to Watch
    Via InvestorPlace
    Where Guardant Health Stands With Analysts
    Via Benzinga
    Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
    From Guardant Health, Inc.
    Via Business Wire
    Evaluating Guardant Health: Insights From 5 Financial Analysts
    Via Benzinga
    Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
    From Guardant Health, Inc.
    Via Business Wire
    Guardant Health Named to TIME100 Most Influential Companies
    From Guardant Health, Inc.
    Via Business Wire
    Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
    From Guardant Health, Inc.
    Via Business Wire
    Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
    Via Benzinga
    Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    FDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer Screening
    Via Benzinga
    Exposures Product Safety
    Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test
    Via Investor's Business Daily
    Exposures Product Safety
    FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
    From Guardant Health, Inc.
    Via Business Wire
    Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
    From Guardant Health, Inc.
    Via Business Wire
    Guardant Health to Participate in Upcoming Investor Conferences
    From Guardant Health, Inc.
    Via Business Wire
    What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
    Via Benzinga
    Exposures Product Safety
    Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
    From Guardant Health, Inc.
    Via Business Wire
    Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Guardant Health, Inc.
    Via Business Wire
    Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
    From Guardant Health, Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.